Media-News

Be the most trusted biotech company

2026-02-28

Henlius Obtains Japan MAH License Strengthening Presence in the World’s Fourth-Largest Pharmaceutical Market
2026-02-28

Henlius Doses First Patient in Phase 2/3 Trial of HLX22 for First-Line Treatment of HER2-Positive Breast Cancer
2026-02-27

EMA CHMP Recommends EU Approval of Henlius’ Pertuzumab Biosimilar HLX11
2026-02-24

Henlius’ Novel anti-PD-1 mAb Serplulimab Will be Available in More Markets
2026-02-16

U.S. FDA Clears IND for Phase 1 Study of Henlius’ Subcutaneous Daratumumab Biosimilar
2026-02-11

First Patient Dosed for a Phase 1b/2 Clinical Trial of PD-L1 ADC HLX43 Combination Therapy in Advanced Colorectal Cancer
2026-02-05

Eisai and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan
2026-02-02

Henlius Holds U.S. Investigator Meeting for HLX22-GC-301, a Head-to-Head Phase 3 Trial vs Standard of Care (±Pembrolizumab) in HER2+ Gastric Cancer
2026-01-27

Henlius Receives an IND Approval for Its PD-L1-Targeting ADC HLX43 in Combination with Anti-PD-1 mAb Serplulimab and Novel Anti-EGFR mAb HLX07